Alnylam’s Blood Pressure Drug: Not Exactly Heartwarming Yet
Alnylam just dropped data from their so-called 'investigational therapy' that was supposed to be the Tesla of blood pressure meds but ended up more like a tricycle. Their Phase 2 trial, aka the 'Thrill of Mediocrity,' didn't significantly lower blood pressure. Yet, in a plot twist worthy of a soap opera reboot, the company decided to plunge forward into a late-stage study—because why quit when you can pretend progress? No dollar amounts or dates were shared, but one thing’s clear: Alnylam is writing a new chapter in the 'Lower Your Expectations' saga. If clinical trials were auditions, this one got a polite nod to keep trying.
Share the Story
(1 of 3)Alnylam’s blood pressure med didn’t budge the dial, but hey, let’s double down on hope and move to late stage—because who doesn’t love trying the same thing harder until it magically works?
Who knew the secret to clinical success is a solid game of pretend? Alnylam’s drug flopped Phase 2 yet gets a free pass to late stage like it’s the kid who flunked math but still makes varsity cheerleading.
'Significantly lowers blood pressure' took a sick day, but Alnylam’s optimism shows up on time and boots—time to double down on science’s version of 'hold my beer.'
Source: Statnews | Published: 8/30/2025 | Author: Elaine Chen
More Articles in Health
Trump Extends Ceasefire Because Iran's Drama Series Needs Another Season
OpenAI CEO’s $27M Mansion Molotoved Amid AI Lab Soap Opera
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Couple Rejects Costco Bulk, Returns to European Grocery Steps and Sanity
Woman Befriends Octogenarian, Learns Aging Is Just 'Old Lady' Bluntness
Woman’s Routine Eye Surgery Turns Into Unplanned MRI Brain Tumor Scare Roadshow
Health Secretary Trades Vaccines for Vegetable Advocacy and Congressional Grousing
Doctors Prescribe Fishing Rods—Because Pills Can’t Cast a Line
